In the clinical practice, Pembrolizumab is already approved by FDA for first-line treatment of patients with metastatic NSCLC who shows ≥50% PD-L1-positive TCs, with no EGFR or ALK genomic tumor aberrations [44]. Here, CD274 is linked to non-small cell lung carcinoma.